Tooney P A, Crawter V C, Chahl L A
Neuroscience Institute of Schizophrenia and Allied Disorders, Sydney, Australia.
Biol Psychiatry. 2001 Mar 15;49(6):523-7. doi: 10.1016/s0006-3223(00)01068-4.
Changes in levels of substance P and substance P-binding sites have been implicated in schizophrenia. However, no studies have used receptor-specific antibodies to directly investigate the substance P (neurokinin 1) receptor in schizophrenia.
We used an antibody directed against the human neurokinin-1 receptor to compare the distribution of neurokinin-1 receptors in the prefrontal cortices from six subjects with schizophrenia and six control subjects, matched for age, gender, and postmortem interval.
In control tissue, dots of neurokinin-1 receptor immunoreactivity were observed in layer I to upper/mid layer III only. In contrast, dots of neurokinin-1 receptor immunoreactivity were observed in all layers of the prefrontal cortex in subjects with schizophrenia, and the density of dots was significantly greater than in control subjects.
This is the first report of increased neurokinin-1 receptor immunoreactivity in the prefrontal cortex in subjects with schizophrenia. These changes may have implications for understanding the pathophysiology of the prefrontal cortex in schizophrenia and for the treatment of this disorder.
P物质水平及P物质结合位点的变化与精神分裂症有关。然而，尚无研究使用受体特异性抗体直接研究精神分裂症患者的P物质（神经激肽1）受体。
我们使用一种针对人类神经激肽-1受体的抗体，比较了6名精神分裂症患者和6名年龄、性别及死后间隔相匹配的对照受试者前额叶皮质中神经激肽-1受体的分布情况。
在对照组织中，仅在I层至III层上/中层观察到神经激肽-1受体免疫反应性的点状分布。相比之下，在精神分裂症患者的前额叶皮质各层均观察到神经激肽-1受体免疫反应性的点状分布，且点状密度显著高于对照受试者。
这是首次报道精神分裂症患者前额叶皮质中神经激肽-1受体免疫反应性增加。这些变化可能对理解精神分裂症前额叶皮质的病理生理学以及该疾病的治疗具有重要意义。
